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There is little doubt that robotic surgery is here to stay. The
real question is if the technologyhas transitioned fromnovelty
and marketing tool to standard of care. The medical literature
is rife with midterm results of robotic procedures as varied as
mitral valve repair and thyroidectomy or prostatectomy and
pancreatic resection. To add to this accumulating knowledge
base, Marulli and colleagues1 now submit their multicenter
data on robotically assisted resection of thymoma.
Minimally invasive approaches to the mediastinum have
been in vogue for well over a decade as technologic ad-
vances in imaging and instrumentation have simplified
video-assisted thoracic surgery (VATS). Long considered
the last bastion of ‘‘bright lights and cold steel,’’ the thorax
has succumbed to the same driving force that has shaped
much of the rest of surgery, namely, the push to perform
equally effective operations through smaller, and less mor-
bid, incisions. To this end, anterior mediastinal operations
(ie, thymectomy) classically performed through sternal
splitting approaches, now often fall under the purview of
VATS. Initially, there was considerable pushback from the
traditionalists, who feared that equivalent operations could
not be performed without sternotomy, whether to palliate
myasthenia gravis (MG) or completely resect thymoma.
Now those discussions appear somewhat safely positioned
in the rearview mirror. Several excellent studies demon-
strate largely equivalent efficacy with much less morbidity
and support VATS approaches for thymic surgery.2-4
Marulli and colleagues1 have taken the push for minimal
access 1 step farther. Their contribution reviews the outcomes
of a 79-patient cohort of robotically assisted thymoma
resections. Although some will argue that the reduction in
morbidity transitioning from VATS to robotic operations is
negligible, intrathoracic instrument articulation and 3-dimen-
sional high-resolution optics clearly permit more elegant and
precise operations to be performed robotically. Robotically
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study revolves around treatment of thymoma, and not MG,
and this study is the largest of its kind in this regard.
Thymoma is a curious tumor and still challenges clini-
cians to develop accurate clinical staging systems. Nonethe-
less, it is considered eminently curable (particularly for
Masaoka stages I-II and World Health Organization histol-
ogy types A, AB, B1, and B2) with complete resection.
Reports of intraoperative tumor capsule rupture and late
presentation of incurable disseminated pleural disease had
guided therapy toward more conservative, open en bloc op-
erations. VATS surgeons have been responsible for begin-
ning to change this paradigm, but may have to make room
for the robotic surgeons, who now report excellent interme-
diate thymoma cure rates that are easily (at this midterm
point) comparable to VATS or open surgical results.
A few lingering issueswill still need to be addressed going
forward. It is unclear if robotically assisted thymic proce-
dures are less morbid (or more effective) than VATs opera-
tions, and given the current climate of cost vigilance, until
a definitive benefit can be demonstrated, it might be difficult
to disseminate this expensive technology. Importantly,much
longer follow-up will be necessary to be certain that roboti-
cally assisted resection recapitulates the open experience,
both from a thymoma recurrence standpoint and durable pal-
liation of MG (which frequently complicates thymoma pre-
sentation). Finally, clear inclusion and exclusion criteria for
robotically assisted thymic resections need to be clarified.
My suspicion is that this is just thefirst of several battlefronts
that surgeons using robotic techniques for thoracic procedures
will be defending, as looming on the horizon are esophagec-
tomy, antirefluxoperations, and lobectomy theaters.The famil-
iar combatants will be the open, VATS, and laparoscopic
surgeons who come armed with the 1 thing that the robot
enthusiasts do not have: Mature data. Let the games begin!
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